Prof Anna Martling speaks to ecancer about a study that she presented at ASCO GI 2025 into the use of low-dose aspirin to reduce recurrence rates in colorectal cancer patients with PI3K pathway alterations.

She explains that in recent years aspirin has been seen to reduce the number of polyps and the size of polyps in patients with a high risk of colorectal cancer.

Prof Martling reports that this study demonstrated that low-dose aspirin for three years reduced the risk of recurrence by more than 50% in colorectal cancer patients with PI3K pathway alterations.